Reata Pharmaceuticals Inc (NASDAQ:RETA) – Research analysts at Svb Leerink reduced their FY2019 earnings per share (EPS) estimates for Reata Pharmaceuticals in a report released on Tuesday, November 12th. Svb Leerink analyst J. Schwartz now forecasts that the company will earn ($7.40) per share for the year, down from their previous estimate of ($7.31). Svb Leerink also issued estimates for Reata Pharmaceuticals’ Q4 2019 earnings at ($3.85) EPS, Q1 2020 earnings at ($1.74) EPS, Q2 2020 earnings at ($5.94) EPS, Q3 2020 earnings at ($2.11) EPS, Q4 2020 earnings at ($2.40) EPS and FY2020 earnings at ($12.14) EPS.
RETA has been the subject of several other research reports. BidaskClub upgraded Reata Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 2nd. ValuEngine upgraded Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald raised their target price on Reata Pharmaceuticals from $180.00 to $250.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. LADENBURG THALM/SH SH restated a “positive” rating and set a $239.00 target price (up previously from $133.00) on shares of Reata Pharmaceuticals in a research report on Wednesday, October 16th. Finally, Leerink Swann set a $230.00 target price on Reata Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Reata Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $247.63.
Reata Pharmaceuticals (NASDAQ:RETA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.25) by ($0.07). Reata Pharmaceuticals had a negative return on equity of 3,282.73% and a negative net margin of 398.84%. The firm had revenue of $8.24 million for the quarter, compared to analysts’ expectations of $7.43 million. During the same period last year, the business earned ($1.07) earnings per share. The firm’s revenue for the quarter was up 59.1% on a year-over-year basis.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Alta Advisers Ltd bought a new position in Reata Pharmaceuticals in the 3rd quarter valued at $12,897,000. BBVA USA Bancshares Inc. bought a new position in Reata Pharmaceuticals in the 3rd quarter valued at $321,000. Tower Research Capital LLC TRC raised its position in Reata Pharmaceuticals by 1,603.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 545 shares of the company’s stock valued at $44,000 after purchasing an additional 513 shares during the last quarter. First Trust Advisors LP raised its position in Reata Pharmaceuticals by 12.2% in the 3rd quarter. First Trust Advisors LP now owns 58,236 shares of the company’s stock valued at $4,676,000 after purchasing an additional 6,319 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new position in Reata Pharmaceuticals in the 3rd quarter valued at $200,000. Hedge funds and other institutional investors own 58.24% of the company’s stock.
In other Reata Pharmaceuticals news, CEO James Warren Huff sold 63,000 shares of Reata Pharmaceuticals stock in a transaction on Friday, September 27th. The stock was sold at an average price of $86.61, for a total value of $5,456,430.00. Following the completion of the transaction, the chief executive officer now owns 164,157 shares in the company, valued at approximately $14,217,637.77. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Elaine Castellanos sold 4,000 shares of Reata Pharmaceuticals stock in a transaction on Monday, October 28th. The shares were sold at an average price of $200.00, for a total value of $800,000.00. Following the completion of the transaction, the chief accounting officer now owns 19,146 shares of the company’s stock, valued at approximately $3,829,200. The disclosure for this sale can be found here. Insiders have sold a total of 101,000 shares of company stock valued at $10,661,430 in the last 90 days. 34.40% of the stock is owned by corporate insiders.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.